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ABSTRACT: Dementia is an important conse-
quence of Parkinson’s disease (PD), with few known
modifiable risk factors. Cumulative exposure to lead, at
levels experienced in the community, may exacerbate
PD-related neural dysfunction, resulting in impaired
cognition. Among 101 persons with PD (‘‘cases’’) and,
separately, 50 persons without PD (‘‘controls’’), we eval-
uated cumulative lead exposure, gauged by tibia and
patella bone lead concentrations, in relation to cognitive
function, assessed using a telephone battery developed
and validated in a separate sample of PD patients. We
also assessed the interaction between lead and case-
control status. After multivariable adjustment, higher
tibia bone lead concentration among PD cases was
associated with worse performance on all of the individ-
ual telephone tests. In particular, tibia lead levels corre-
sponded to significantly worse performance on a
telephone analog of the Mini–Mental State Examination
and tests of working memory and attention. Moreover,
higher tibia bone lead concentration was associated
with significantly worse global composite score
encompassing all the cognitive tests (P 5 0.04). The
magnitude of association per standard deviation incre-
ment in tibia bone lead level was equivalent to the dif-
ference in global scores among controls in our study,
who were approximately 7 years apart in age. The tibia
lead-cognition association was notably stronger within
cases than within controls (Pdifference 5 0.06). Patella
bone lead concentration was not consistently associ-
ated with performance on the tests. These data provide
evidence suggesting that cumulative exposure to lead
may result in worsened cognition among persons with
PD. VC 2012 Movement Disorder Society
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Dementia is a major health concern in individuals
with Parkinson’s disease (PD), with a prevalence in
PD patients estimated to be two to six times that in
persons without PD.1 PD patients who develop de-
mentia have higher risks of institutionalization and
mortality, their healthcare is more costly, and their
caregivers report more stress.2–5 Even PD patients
without clinically evident intellectual deterioration ex-
hibit subtle deficits in specific areas of cognitive func-
tion, such as verbal fluency, executive functions,
visuospatial skills, and recall memory; these deficits,
too, are associated with increased risk for disability
and hospitalization.6–8 Nonetheless, few risk factors,
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particularly modifiable ones, have been identified.
Whether environmental toxicants are involved in the
development of PD-related dementia has not been
addressed, although emerging evidence suggests that
exposure to toxicants, such as lead, may affect risk of
neurodegenerative conditions in adulthood.
Lead is a well-established neurotoxicant, and a
growing body of data suggest that cumulative expo-
sure to lead corresponds to poor cognitive function in
older adulthood.9–11 Impaired cognitive function fre-
quently portends the development of dementia in per-
sons with PD.12,13 Recent data also indicate that lead
exposure is associated with elevated risk of PD.14–16
Exposure to lead may have ramifications for cognition
in PD, because lead, acting on several targets, may
exacerbate damage that is already present in PD. One
likely mechanism is oxidative stress (OS): Lead indu-
ces iron-dependent lipid peroxidation and also inter-
feres with antioxidant capacity.17–20 Lead damages
mitochondria,21 which can result in neural excitotox-
icity and apoptosis, and interferes with neurotransmit-
ter storage and release.22 In particular, lead appears to
disrupt processes involved in cholinergic, glutamater-
gic, and dopaminergic systems,22,23 pathways through
which it may impair learning ability and executive
function. Because lead accumulates throughout the
brain,24 its toxic effects are not restricted to the SN,
the anatomic region primarily affected in PD. Rather,
lead exposure may magnify the burden of PD on cog-
nition, reducing the available mechanisms for compen-
sating for PD-related impairments.
PD is thought to involve oxidative damage to, and
mitochrondrial dysfunction in, the dopaminergic cells
of the SN.25,26 Given the overlap of PD and lead-ex-
posure pathologies, we hypothesized that higher cu-
mulative exposure to lead corresponds to worse
cognitive functioning in persons with PD. In addition,
we explored a secondary hypothesis: that lead-induced
dysfunction and damage on a background of PD-
related damage and impaired neurotransmitter systems
may result in cognitive effects of lead that are more
pronounced than among otherwise healthy older
adults.
We evaluated these relationships in a subset of par-
ticipants enrolled in an existing study in which partici-
pants’ cumulative exposure to lead was assessed by
noninvasive in vivo K X-ray fluorescence (KXRF)
spectrometry measurements of lead content in bone.
Patients and Methods
Study Participants
We developed a telephone-based assessment of cog-
nitive functions that typically decline in PD, and we
validated this assessment against an in-person assess-
ment (see Supporting Materials, part 1). We recruited
participants for our study of lead exposure and cogni-
tive function from an existing case-control study of
lead exposure and PD (see Supporting Materials, part
2).14 To ensure a broad representation of lead expo-
sure and key covariates among participants in the cog-
nitive study, we selected cases (persons with PD) and
controls (persons without PD) within strata of previ-
ously measured tibia bone lead concentration (tertiles),
age (<70 and 70þ), and sex. Of the 126 cases, we
invited for cognitive assessments, 4 had died, and of
those remaining, 9 (7%) could not be located, 8 (7%)
were too ill to participate, and 4 (3%) refused. Of the
60 controls invited, we were unable to locate 7 (12%)
and 3 (<1%) refused. Altogether, we completed
assessments of 101 cases and 50 controls. All cases
were confirmed by movement disorder specialists using
the UK Brain Bank Criteria.27 This study was
approved by the human research committees of the
Brigham and Women’s Hospital (Boston, MA) and the
Beth Israel Deaconess Medical Center (Boston, MA).
Written informed consent was obtained from partici-
pants in the validation study. Participants in the lead
exposure study provided their written informed con-
sent for the assessment of their lead exposure and oral
consent for their cognitive assessment.
Development and Validation of Telephone
Cognitive Battery
We developed our telephone cognitive assessment
battery based on a validated telephone battery for
assessing age-related cognitive decline.28 To this bat-
tery, we added tests of cognitive domains that typi-
cally decline in PD. To keep the battery at a length
acceptable to participants, we removed tests from the
original battery that likely would not provide addi-
tional useful information about PD patients’ cognitive
status. Altogether, the telephone battery contained
nine tests. The Telephone Interview for Cognitive Sta-
tus (TICS)29 is a test of global cognition modeled on
the Mini–Mental State Examination30; scores on the
two tests are strongly correlated (Pearson’s correla-
tion: 0.94).29 The battery also contained a test of
delayed recall of the TICS 10-word list, as well as a
test of delayed recognition of these words. For a test
of category fluency, participants were asked to name
as many animals as they could in 1 minute,31 and for
a test of phonemic fluency, participants were asked to
name as many words beginning with letter ‘‘f’’ as they
could in 1 minute.32 Both of these tests also gauge
executive function and psychomotor speed. The Digit
Span Forward and Digit Span Backward tests meas-
ured working memory and attention.32 Finally, we
administered an oral version of the Trail Making Test
(TMT)32 of psychomotor speed and executive function
in which we asked participants to count aloud from 1
to 52 as quickly and as clearly as possible (TMT Part
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A) and then to count aloud from 1 to 26, but interspers-
ing between each number its coordinating ordinal letter
(i.e., 1-A, 2-B, 3-C, etc.; TMT Part B). Both counting
exercises were timed, and we subtracted the time to per-
form Part A from the time to perform Part B, in sec-
onds, to obtain an orally based estimate of a ‘‘Trails B
minus A’’ score. We also explored an alternative mea-
sure from this test: the difference between the number
reached in Part A at 10 seconds and the number reached
in Part B at 30 seconds. Because nearly all participants
complete the test up to these time points even if they do
not complete the entire oral TMT, this metric poten-
tially minimizes missing data.
Assessment of Cumulative Exposure to Lead
We assessed participants’ cumulative exposure to
lead using KXRF spectrometric estimates of lead concen-
tration in their tibia and patella bones. Tibia bone is pri-
marily cortical bone, in which lead has a slow turnover
rate—estimated at a half-life of over 40 years33—making
it a good surrogate for lifetime exposure. Patella bone is
primarily trabecular bone; lead in patella turns over at a
faster rate, with a half-life of less than a decade.
Together, these exposure measures can help determine
the relevant exposure interval or duration.
Thirty-minute bone lead measurements were taken
with a KXRF instrument of the left tibia and patella, after
each region had been washed with a 50% solution of iso-
propyl alcohol.34 The tibia was measured at midshaft—
the midpoint between the tibial plateau and the medial
malleolus. The KXRF beam collimator was sited perpen-
dicular to the flat bony surface of the tibia and at 30
degrees in the lateral direction for the patella. Tibia and
patella bone lead measurements with estimated uncertain-
ties greater than 10 and 15 lg/g of bone, respectively,
were excluded because these measurements usually reflect
excessive subject movement during the measurement.
Statistical Analysis
We evaluated the validity of the telephone cognitive
assessment using Spearman’s correlations between the
individual in-person/telephone test pairs and between in-
person and telephone global scores. Global scores were
computed as the average z score from each component
score (where z scores were computed using the validation
population means and standard deviations [SDs]).
To describe our data from the lead-exposure study,
we computed mean patella and tibia bone lead con-
centrations across levels of key participant characteris-
tics and tested differences across these levels using F
tests. For this part of the study, we computed z scores
for each cognitive test using the lead study partici-
pants’ means and SDs; global cognitive scores were
the average z score from each component of the tele-
phone test. Using data from the cases, we fit a series
of linear regression models to evaluate the association
of cumulative lead exposure with cognition in PD. We
regressed the individual telephone cognitive test z
score onto the cumulative lead-exposure measure,
with separate models for each cognitive test and each
lead-exposure measure (i.e., patella and tibia bone
lead concentration), and report on differences in
standardized cognitive score per SD increment in each
bone lead measure (10-lg/g increment in bone lead
concentration). All models were adjusted for age at
cognitive assessment, sex, race (i.e., white, not white,
or missing), education (high school diploma or less,
associate’s degree, bachelor’s degree, or master’s or doc-
toral degree), and pack-years of cigarette smoking (never
smoked, smoked for <20 pack-years, or smoked for 20
pack-years). We conducted sensitivity analyses in which
we further adjusted for age of onset of PD symptoms
(available for 66% of cases), changed the cut-point for
pack-years to 10 (median among ever-smokers), and in
which we substituted the alternative trails difference
scores for the original ‘‘B minus A’’ scores in computing
the global cognitive score. To provide context for the
magnitude of our findings, we estimated the sex-, race-,
education-, and smoking-adjusted association between
age and the global cognitive score among the controls;
the beta coefficient for age served as a benchmark for
interpreting the beta coefficients for bone lead.
We further explored whether the telephone battery
could detect differences between persons with and
without PD by incorporating data from controls in
these models and comparing cases’ and controls’ cog-
nitive test scores. To explore the possibility that PD
and lead exposure have a synergistic effect on cogni-
tive function, we also fit multivariable-adjusted models
that incorporated controls. In these models, we added
terms for case-control status as well as a cross-product
between case-control status and the lead-exposure
measure. To ensure overlap of cases’ and controls’
ages, we restricted these analyses to participants who
were 60 to 80 years of age at cognitive testing.
Results
Validation of the Telephone Cognitive
Assessment
Among the 10 participants in our validation study,
performance on the in-person cognitive tests corre-
sponded well to performance on the telephone tests
(Table 1; Supporting Materials; Supporting Table 1).
Importantly, global scores computed from the two
modes of assessment were significantly correlated
(Spearman’s correlation: 0.72; P ¼ 0.03; Figure 1).
Association of Cumulative Exposure to Lead
With Cognitive Function in Persons With PD
Among participants with PD, patella lead concentra-
tions were significantly lower in those with less-
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extensive smoking history, and tibia lead concentra-
tions were significantly lower in those with more-for-
mal education (master’s degree or more) (Table 2).
Higher tibia lead concentration was associated with
worse performance on all of the telephone cognitive
tests among these persons with PD (Table 3). In par-
ticular, in multivariable-adjusted analyses, tibia lead
levels corresponded to significantly worse performance
on the TICS (P ¼ 0.05), the Digit Span Forward test
(P ¼ 0.03), and the Digit Span Backward test
(P¼0.05). Tibia lead’s association with worse per-
formance on the ‘‘f’’ naming test was borderline sig-
nificant, as well (P ¼ 0.06). Furthermore, higher tibia
lead concentration was associated with significantly
worse overall performance, as gauged by the global
cognitive score (P ¼ 0.04). The difference in global
scores per SD increment in tibia lead concentration
was equivalent to the difference in scores among con-
trols in our study, who were approximately 7 years
apart in age. By contrast, patella bone lead concentra-
tion was not consistently associated with cognitive
performance. Additional adjustment for age of PD
symptom onset or alternative categorizations of smok-
ing revealed similar findings. Findings were also simi-
lar when we substituted the alternative trails
difference test score for the original oral ‘‘B minus A’’
score in computing the global score.
Association of Lead Exposure With Cognitive
Function by PD Status
Among all study participants, bone lead concentra-
tions were lowest in the youngest age group; patella
lead concentrations were significantly lower in those
with less-extensive smoking history and in those with
more-formal education (Supporting Table 2). On aver-
age, individuals with PD performed worse than con-
trols on all of the cognitive tests. For example, in
analyses adjusted for age, sex, race, smoking history,
and tibia lead level, global cognitive scores of the
cases were, on average, 0.32 standard units worse
than scores of the controls (95% confidence interval
[CI]: 0.50 to 0.13). The inverse association of tibia
lead level with global cognition was pronounced
among the cases, but absent among the controls
(Pdifference in tibia Pb associations ¼ 0.06). In a model that
included both cases and controls, an SD increment in
FIG. 1. Correlation between global scoresa from in-person and tele-
phone cognitive assessments (N 5 9).
TABLE 1. Spearman correlations* between analog cognitive test scores from the in-person assessment and
telephone cognitive assessments




MDRS TICS Global 0.60 0.07
Learning and memory tests
Delayed word recall from CVLT, total correct Delayed 10-word recall Verbal learning and memory 0.43 0.2
Delayed word recall from CVLT, total correct Delayed 10-word recognition 0.29 0.4
Fluency tests
Animal naming Animal naming Semantic fluency 0.80 0.006
‘‘a’’ naming ‘‘f’’ naming Phonemic fluency 0.60 0.07
‘‘f’’ naming ‘‘f’’ naming Phonemic fluency 0.85 0.002
TMTs
Trails A Oral trails A Psychomotor speed 0.29 0.4
Trails B Oral trails B Psychomotor speed,
executive function
0.75 0.02
Trails B minus A Oral trails B minus A Executive function 0.47 0.2
Trails B minus A Number reached by 10 seconds
(A) minus letter-number pair
reached by 30 seconds (B)
Executive function 0.53 0.1
*N ¼ 10 for all pairs, except for in-person and oral Trails B and in-person and oral trails B minus A.
Abbreviations: Mattis Dementia Rating Scale; CVLT, California Verbal Learning Test.
E X P O S U R E T O L E A D A N D C O G N I T I O N I N P D
Movement Disorders, Vol. 28, No. 2, 2013 179
tibia lead level among the cases corresponded to a
global cognitive score that was worse by 0.12 stand-
ard units (95% CI: 0.22 to 0.01); but among con-
trols, tibia lead level was not significantly associated
with global score (difference in score per 10-lg/g-unit
increment in tibia lead: 0.06; 95% CI: 0.09 to
0.20). We did not find evidence of an interaction
between patella lead and PD; however, the power to
detect effects in controls was limited in this small
sample.
TABLE 2. Mean patella and tibia bone lead concentrations by key characteristics of participants with PD in the study
of lead exposure and cognition
Patella Bone Lead Tibia Bone Lead
Characteristic N (%)*
Mean Concentration
(SD), lg/g Bone P Value N (%)*
Mean Concentration
(SD), lg/g Bone P Value
Age at cognitive interview, years 0.01 0.5
54.0–64.9 20 (20) 6.3 (11.5) 20 (20) 5.1 (11.5)
65.0–69.9 35 (36) 11.1 (11.1) 35 (35) 9.3 (10.9)
70.0–74.9 24 (24) 6.6 (10.3) 25 (25) 7.1 (8.4)
75.0–80.9 19 (19) 14.7 (10.2) 21 (21) 8.8 (11.8)
Sex 0.2 0.9
Female 44 (45) 8.4 (10.2) 45 (45) 8.0 (10.5)
Male 54 (55) 10.8 (9.7) 56 (55) 7.7 (10.8)
Race 0.7 >0.9
White 88 (87) 9.4 (10.1) 88 (87) 7.9 (10.9)
Other 5 (5) 9.4 (5.1) 5 (5) 7.8 (9.4)
Missing 8 (8) 12.7 (10.2) 8 (8) 6.7 (8.5)
Educational attainment 0.2 0.04
Up through high school 19 (19) 11.6 (10.3) 19 (19) 9.9 (9.1)
Associate’s degree 12 (12) 10.2 (10.7) 12 (12) 10.9 (11.5)
Bachelor’s degree 28 (29) 11.8 (8.8) 29 (29) 10.4 (12.5)
Master’s or doctoral degree 39 (40) 7.1 (10) 41 (41) 4.2 (8.7)
Smoking history 0.004 0.07
Never smoked 58 (59) 6.8 (9.0) 59 (58) 6.2 (10.8)
Ever smoked 40 (40) 13.8 (9.7) 42 (42) 10.1 (10.1)
By dosea 0.001 0.2
<20 pack-years 30 (75) 12.7 (9.5) 32 (76) 9.7 (10.4)
20þ pack-years 10 (25) 17.3 (10.1) 10 (24) 11.3 (9.3)
Age of PD symptom onset, years 0.3 0.7
35.0–54.9 12 (19) 7.5 (13.3) 12 (18) 9.4 (12.0)
55.0–64.9 30 (48) 7.9 (8.4) 31 (47) 6.5 (11.1)
65.0–78.9 21 (33) 12.1 (10.7) 23 (35) 7.6 (10.7)
*Percentages are of the number of participants with valid data on the bone lead measure and characteristic.
aPercentages shown are among ever-smokers.
TABLE 3. Adjusted* difference (95% CI) in standardized cognitive score per 10-lg/g increment in bone lead
concentration
Patella Bone Lead Tibia Bone Lead
Cognitive Test N Difference (95% CI) P Value N Difference (95% CI) P Value
Telephone interview for cognitive
status (TICS)
98 –0.08 (–0.32 to 0.15) 0.5 101 –0.20 (–0.40 to –0.00) 0.05
Delayed 10-word recall 97 0.05 (–0.18 to 0.28) 0.7 100 –0.04 (–0.23 to 0.16) 0.7
Delayed 10-word recognition 94 0.01 (–0.22 to 0.24) 0.9 96 –0.01 (–0.21 to 0.20) >0.90
Animal naming 98 –0.11 (–0.32 to 0.10) 0.3 101 –0.11 (–0.29 to 0.07) 0.2
‘‘F’’ naming 97 –0.07 (–0.30 to 0.17) 0.6 100 –0.19 (–0.39 to 0.01) 0.06
Digit Span Forward 97 –0.02 (-0.27 to 0.22) 0.9 100 –0.23 (-0.43 to -0.03) 0.03
Digit Span Backward 97 0.05 (-0.17 to 0.27) 0.7 100 –0.19 (-0.37 to -0.00) 0.05
Oral trails B minus Aa 85 0.03 (-0.23 to 0.28) 0.8 87 –0.06 (-0.29 to 0.17) 0.6
Global score 85 –0.01 (-0.14 to 0.13) 0.9 87 –0.13 (-0.25 to -0.01) 0.03
*Analyses adjusted for age at cognitive assessment, sex, race, education, and smoking history.
aScores reversed so that lower score reflects worse performance.
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Discussion
We found that higher cumulative exposure to lead,
gauged by tibia bone lead concentration, is associated
with worse cognition in persons with PD, independent
of age, sex, race, education, and smoking history. The
decrement in global cognitive score per SD increment
in tibia lead was similar to the decrement in scores we
observed between persons without PD who were 7
years apart in age. Our findings further suggest that
lead exposure may specifically exacerbate the cognitive
impairment caused by PD, although our power to
detect effects in controls was lower. The significant
associations in our study were confined to those per-
taining to tibia lead concentration. Associations with
patella bone lead concentration were inconsistent and
not significant. This suggests that long-term exposure
to lead may have greater influence than more-recent
exposure on cognition in PD, or, alternatively, that
tibia lead, by integrating exposures over longer peri-
ods, is more likely than patella lead to capture the pe-
riod of exposure relevant to cognition in PD. Our
findings, in tandem with the previously observed asso-
ciation between higher tibia lead concentration and
PD risk,14 are also consistent with the possibility that
lead exposure influences the development of a particu-
lar phenotype of PD that entails more-rapid onset of
cognitive decline and dementia.13,35
This study has several limitations and strengths. To
assess participants’ cognition, we used a validated
telephone-based, rather than an in-person, cognitive
battery. Telephone-based cognitive assessments are
receiving increasing use in large-scale research on
aging-related cognitive decline (e.g., as described else-
where28,36,37) and they offer some practical advan-
tages over in-person assessments, notably enhanced
participation. This advantage is especially important
for studies involving participants who have mobility
difficulties, such as those with PD. By design, the tele-
phone battery could not include tests of visuospatial
function, which is adversely affected in PD13,38 and by
exposure to lead.9 Yet, it is clear that other cognitive
functions that the battery measures well (attention,
memory, and executive function) decline in PD.13,38
Moreover, in our data, these functions, particularly
attention and executive function, appeared to be dele-
teriously associated with lead exposure.
Our study was small and cross-sectional in design.
In spite of the study’s size, we detected several strong,
significant associations between tibia lead concentra-
tions and cognitive function. A larger study would
have provided greater statistical power to detect more-
subtle effects, including, potentially, those correspond-
ing to patella bone lead concentration. Likewise, a
larger sample of persons without PD would have
improved our capacity to detect and precisely estimate
the tibia lead-cognition association in this group.
Although studies of community-exposed adults that
included more than 10 times as many participants
were able to detect significant adverse associations
between tibia lead level and cognition, these associa-
tions were comparably small (approximately one third
the association in our participants with PD).10,39
Although the cross-sectional design precluded us
from evaluating longitudinal changes in cognition, it is
unlikely that reverse causation is a concern in our
study. The extended exposure windows captured by
the bone lead measures meant that lead exposure pre-
ceded the cognitive outcomes and, especially in the
case of tibia lead, the onset of PD itself.
In this observational study, it remains possible that
our findings could be explained by confounding. One
potential source of confounding is duration of PD. As
described previously,14 in the recent environment of
relatively low lead levels, the normal process of bone
formation could dilute bone lead concentrations. PD-
related osteopenia could slow this process40; as a
result, for a given history of exogenous lead exposure,
shorter duration of PD at the time of lead exposure
assessment could result in lower bone lead concentra-
tions. Longer duration of PD is also associated with
adverse cognitive sequelae.2 Yet, disease duration is
unlikely to be an important source of confounding in
our data, because further adjustment for age at PD
symptom onset did not change our findings. More-
over, because vascular perfusion is greater in trabecu-
lar than in cortical bone, the link between disease
duration and osteopenia would be more likely to influ-
ence association estimates for patella lead than for
tibia lead. However, findings from patella lead analy-
ses were null. Unmeasured dimensions of socioeco-
nomic status also may be a potential source of
confounding. By the study enrollment process, our
participants demonstrated their similar access to
healthcare, and we adjusted all analyses for age, sex,
race, education, and smoking history. Moreover, in al-
ternative analyses restricted to the 41 PD cases with a
masters or doctoral degree, tibia bone lead concentra-
tion remained associated with significantly worse
global cognitive score.
Findings from several studies of adults with occupa-
tional and community-level exposures to lead have
identified associations of cumulative lead exposure
with both poor cognition9–11 and PD.14–16 The present
study is the first of which we are aware to identify an
association between lead exposure and cognition
among persons with PD. If this represents a causal
relationship, then, in addition to being a primary risk
factor for PD, lead exposure would be among the few
known modifiable risk factors for cognitive decline
and, potentially, PD-related dementia. Lead’s involve-
ment could also reveal mechanisms of cognitive
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decline in PD. By inducing OS,17,18 impairing the brain’s
ability to respond to OS,19,41 damaging mitochondria,
and interfering with calcium-dependent enzymes,
chronic exposure to lead may increase the vulnerability
of cortical and subcortical regions of a PD-affected brain
to inflammation, impaired neurotrophic capacity, and
apoptosis,2 all of which may adversely affect cognitive
functioning, particularly working memory.
Conclusion
In summary, this study of persons with PD provides evi-
dence that higher levels of cumulative exposure to lead
are associated with worse cognitive function, suggesting
yet another way in which community-level exposure to
lead manifests itself in chronic diseases of older age.
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